Press Release - August 26, 2021
Heidelberg, Germany, November 9, 2021 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021.
Stifel 2021 Virtual Healthcare Conference (November 15 – 17, 2021)
Date: Monday, November 15, 2021
Presentation Time: 8:00 a.m. EST
Jefferies London Healthcare Conference 2021 (November 16 – 19, 2021)
Date: Friday, November 19, 2021
Presentation Time: The Fireside Chat will become available on November 18 at 3:00 a.m. EST
For more information or to schedule a one-on-one meeting with Affimed’s management, please contact your conference representative or Alex Fudukidis via email at firstname.lastname@example.org or phone at +1 (917) 436-8102.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the company’s people, pipeline and partners, please visit: https://www.affimed.com.
Director, Head of Investor Relations
Tel.: +1 (917) 436-8102